Developer docs
API playgroundTry for free, no card

Search company profiles

Nexilico

Full company profile

uuid0002vd6

Namestring
Nexilico
Legal namestring
Nexilico, Inc.
Websiteurl
nexilico.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Nexilico, Inc. is a privately held biotech company founded in 2019 and headquartered at 98 Amberfield Ln, Danville, California (previously listed in Berkeley). The company develops AI-driven computational platforms for gut microbiome precision medicine, anchored by its proprietary "microbiome digital twin" technology. This modality-agnostic platform runs massively parallel in silico simulations of microbial community dynamics under therapeutic perturbations, capturing interactions across thousands of metabolic features and tracking how microbial strains respond to interventions over time. As of July 2025 the platform had executed over 1.5 million virtual experiments and 40 billion metabolic calculations, producing what the company describes as the largest virtual microbiome dataset to date.

The company's core product, the Microbiome Digital Twin Platform, is built on mathematical, biophysical, and systems biology algorithms and underpins several specialized research programs: an AI-Driven Discovery Platform for precision microbiome therapeutics (NSF Phase II SBIR funded), a Gut Microbiome Drug Metabolism Prediction solution (NIH NCATS funded in collaboration with UC Berkeley and Microvi Biotech), a Gut Microbiome Response Prediction Platform (NIH NIGMS funded), and a Xenobiotic Toxicity Solution initially targeting arsenic detoxification (NIH NIEHS STTR funded). These applications span therapeutic areas including necrotizing enterocolitis (with Siolta Therapeutics), metabolic disorders, oncology, and inflammatory diseases.

Nexilico operates a B2B technology platform model serving pharmaceutical and biotech companies developing microbiome-based therapeutics and live biotherapeutic products. Revenue mechanics are pre-commercial: the company funds R&D almost entirely through non-dilutive NIH and NSF SBIR/STTR grants (cumulative identified government funding exceeds $3M since 2019, including a $1M NSF Phase II award in 2023), supplemented by collaborative development agreements with potential milestone and royalty economics (notably the Siolta Therapeutics co-development deal announced September 2024), and technology licensing intent. Infrastructure is supported by AWS Activate, NVIDIA Inception Program (joined March 2024), and Google for Startups Cloud Program at the Scale Tier (joined April 2025, up to $350K in cloud credits). The company has 1-10 employees, is led by co-founder and CEO Mohammad Soheilypour and Director of R&D Wyatt Hartman, and has no disclosed equity venture capital investors.

Short descriptiontext

Nexilico, Inc. is a Danville, California-based biotech company developing AI-driven computational platforms for gut microbiome precision medicine. Its proprietary microbiome digital twin technology runs large-scale in silico simulations, serving pharmaceutical and biotech firms via licensing and collaborative development agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDanville, United States
HQ citystring
Danville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome precision medicine, digital twin simulation, computational biology platform, AI drug discovery, gut microbiome therapeutics
Industry3 codes
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Computational Biology / Microbiome Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Licensing of AI-driven microbiome discovery platform and digital twin technology to pharmaceutical and biotech companies for drug discovery and development.

nexilico.com
2Collaborative Development Agreements
TypeSubscription Recurring
Description

Partnerships with other biotech companies (e.g., Siolta Therapeutics) for co-development of microbiome-based therapeutics with potential milestone and royalty payments.

nexilico.com
3Government Grants and SBIR Funding
TypeSubscription Recurring
Description

NIH and NSF SBIR/STTR grants providing non-dilutive funding for R&D activities across multiple therapeutic areas.

nexilico.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Nexilico develops and operates a proprietary Microbiome Digital Twin Platform—an AI-driven, massively parallel computational platform that simulates the dynamic behavior of microbial communities under perturbations, capturing thousands of metabolic features and tracking strain-level responses over time. The platform powers a modality-agnostic discovery engine for designing precision microbiome therapeutics across multiple disease areas (e.g., necrotizing enterocolitis, drug metabolism, xenobiotic toxicity). It has completed over 1.5 million virtual experiments and 40 billion metabolic calculations, providing biotech, pharma, and research collaborators with in silico prediction capabilities that reduce reliance on costly trial-and-error laboratory studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 1.5 million virtual experiments completed and 40 billion metabolic calculations simulated
+2 more records
Product overview1 text field

Nexilico is a biotech company offering a unified precision microbiome engineering platform powered by proprietary AI-driven technology. The core offering consists of the Microbiome Digital Twin Platform, which enables virtualized microbiome experimentation at population scale through in silico simulations (over 1.5 million simulations and 40 billion metabolic calculations). This platform serves as the foundation for specialized applications including the AI-Driven Discovery Platform for precision microbiome therapeutics, the Gut Microbiome Response Prediction Platform for personalized therapeutic response modeling, the Gut Microbiome Drug Metabolism Prediction solution, and the Xenobiotic Toxicity Solution for environmental toxin neutralization. The platform is modality-agnostic, supporting development of diverse therapeutic strategies across multiple disease areas including necrotizing enterocolitis (in partnership with Siolta Therapeutics), metabolic disorders, oncology, and inflammatory diseases.

Product and service3 records
1Microbiome Digital Twin Platform
CategoryComputational Biology / Digital Twin Platform
Description

A massively parallel simulation platform that models the dynamic behavior of microbial communities under perturbations, capturing interactions across thousands of metabolic features and tracking how microbial strains respond to changes over time. Built on mathematical, biophysical, and systems biology algorithms, it produces the largest virtual microbiome dataset to date. Used by biotech, pharma, and academic collaborators to virtualize microbiome experimentation.

2AI-Driven Discovery Platform
CategoryAI Drug Discovery / Precision Therapeutics
Description

A computational discovery platform based on microbiome digital twin technology that enables disease-agnostic design of precision microbiome therapeutics with enhanced effectiveness as evaluated through microbiome signatures and clinical response. Targeted at biotech and pharmaceutical companies seeking to accelerate microbiome-targeted therapeutic development.

3Precision Microbiome Engineering Platform
CategoryMicrobiome Precision Medicine Platform
Description

A modality-agnostic AI-driven discovery platform that enables microbiome precision medicine and drives the development of diverse therapeutic strategies across a range of diseases, incorporating proprietary microbiome digital twin technology. Designed for biotech and pharma partners seeking integrated precision microbiome engineering capabilities.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-07-07
Description

AWS Activate program providing cloud infrastructure and technical resources that enabled scaling of in silico microbiome simulations to 1.5 million experiments.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-04-01
Description

Accepted into Google for Startups Cloud Program at Scale Tier, gaining access to up to $350,000 in Google Cloud credits, expert mentorship, exclusive technical resources, go-to-market guidance, and direct integration with Google Cloud's AI/ML ecosystem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Collaboration agreement to address necrotizing enterocolitis (NEC) using innovative microbial therapeutics. Combines Nexilico's modality-agnostic AI-driven discovery platform with Siolta's end-to-end live biotherapeutic product (LBP) platform. Aims to develop multistrain LBP for preterm infants.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-03-08
Description

Accepted into NVIDIA Inception Program for AI startups, providing access to advanced computing technologies, expertise, and global network of venture capitalists to accelerate microbiome engineering technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-13
Description

Collaboration with UC Berkeley and Microvi Biotech on NIH NCATS grant to develop computational solution for predicting gut microbiome-mediated drug metabolism and its effect on drug efficacy and toxicity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-16
Description

Collaboration on developing precision biological processes combining Microvi's MicroNiche Engineering (MNE) Platform with Nexilico's machine learning and microbiome modeling platforms. Multiple NIH SBIR grants awarded ($1.12M NIEHS, NCATS funding) for microbiome-based technology development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Second Genome
TypeDirect peer
Description

Second Genome applies microbiome science to drug discovery in inflammation and metabolic disease, combining computational biology with therapeutic development — a similar platform-plus-pipeline model to Nexilico's digital twin approach.

TypeDirect peer
Description

Microvi Biotech provides microbiome-based biocatalysis and precision biological processes, and is Nexilico's repeated NIH co-awardee. Both target microbiome engineering for environmental and biomedical applications, sharing grant funding and research collaboration.

TypeEmerging player
Description

Turbine builds AI-driven simulation platforms for cell biology and drug discovery, including in silico experiments on cancer cell behavior. Comparable to Nexilico as an AI simulation platform applied to life sciences R&D, though focused on oncology rather than microbiome.

TypeBroad incumbent
Description

Ginkgo Bioworks is a horizontal synthetic biology platform that designs and programs microbial cells for industrial and biomedical applications. A broad incumbent with a similar platform-plus-applications model but vastly larger scale and capital base.

TypeBroad incumbent
Description

Recursion uses high-throughput experimental biology combined with AI/ML to discover new therapeutics. Operates a tech-bio platform similar in spirit to Nexilico's digital twin concept, but at much larger scale with publicly disclosed pipeline programs.

TypeDirect peer
Description

Insitro combines machine learning with high-throughput biology to discover and develop therapeutics. Like Nexilico, Insitro uses AI-driven predictive modeling as a core platform asset to accelerate drug discovery across multiple indications.

TypeEmerging player
Description

CytoReason builds AI models of the human immune system and disease biology used by pharmaceutical companies for drug discovery. Comparable as an AI-driven biological simulation platform serving pharma/biotech clients, though focused on immune biology rather than microbiome.

TypeBroad incumbent
Description

Seres Therapeutics is a clinical-stage microbiome therapeutics company with an approved product (Vowst) and multiple pipeline programs. A broad incumbent in microbiome drug development with established pharma partnerships and much larger capital base than Nexilico.

TypeDirect peer
Description

Siolta Therapeutics develops live biotherapeutic products for inflammatory diseases, including NEC — Nexilico's named collaboration partner. Both companies operate in the microbiome therapeutics space with complementary platforms (computational discovery vs. LBP development).

TypeDirect peer
Description

Vedanta Biosciences is a clinical-stage microbiome therapeutics company developing defined bacterial consortia for immune-mediated diseases. Comparable as a microbiome drug discovery company pursuing live biotherapeutics, though at significantly larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nexilico

Computational Biology / Microbiome Discovery Platformnexilico.com

Nexilico, Inc. is a Danville, California-based biotech company developing AI-driven computational platforms for gut microbiome precision medicine. Its proprietary microbiome digital twin technology runs large-scale in silico simulations, serving pharmaceutical and biotech firms via licensing and collaborative development agreements.

What Nexilico does

Nexilico, Inc. is a privately held biotech company founded in 2019 and headquartered at 98 Amberfield Ln, Danville, California (previously listed in Berkeley). The company develops AI-driven computational platforms for gut microbiome precision medicine, anchored by its proprietary "microbiome digital twin" technology. This modality-agnostic platform runs massively parallel in silico simulations of microbial community dynamics under therapeutic perturbations, capturing interactions across thousands of metabolic features and tracking how microbial strains respond to interventions over time. As of July 2025 the platform had executed over 1.5 million virtual experiments and 40 billion metabolic calculations, producing what the company describes as the largest virtual microbiome dataset to date.

The company's core product, the Microbiome Digital Twin Platform, is built on mathematical, biophysical, and systems biology algorithms and underpins several specialized research programs: an AI-Driven Discovery Platform for precision microbiome therapeutics (NSF Phase II SBIR funded), a Gut Microbiome Drug Metabolism Prediction solution (NIH NCATS funded in collaboration with UC Berkeley and Microvi Biotech), a Gut Microbiome Response Prediction Platform (NIH NIGMS funded), and a Xenobiotic Toxicity Solution initially targeting arsenic detoxification (NIH NIEHS STTR funded). These applications span therapeutic areas including necrotizing enterocolitis (with Siolta Therapeutics), metabolic disorders, oncology, and inflammatory diseases.

Nexilico operates a B2B technology platform model serving pharmaceutical and biotech companies developing microbiome-based therapeutics and live biotherapeutic products. Revenue mechanics are pre-commercial: the company funds R&D almost entirely through non-dilutive NIH and NSF SBIR/STTR grants (cumulative identified government funding exceeds $3M since 2019, including a $1M NSF Phase II award in 2023), supplemented by collaborative development agreements with potential milestone and royalty economics (notably the Siolta Therapeutics co-development deal announced September 2024), and technology licensing intent. Infrastructure is supported by AWS Activate, NVIDIA Inception Program (joined March 2024), and Google for Startups Cloud Program at the Scale Tier (joined April 2025, up to $350K in cloud credits). The company has 1-10 employees, is led by co-founder and CEO Mohammad Soheilypour and Director of R&D Wyatt Hartman, and has no disclosed equity venture capital investors.

Nexilico firmographics

Firmographics
Name
Nexilico
Legal name
Nexilico, Inc.
Website
https://nexilico.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Nexilico, Inc. is a Danville, California-based biotech company developing AI-driven computational platforms for gut microbiome precision medicine. Its proprietary microbiome digital twin technology runs large-scale in silico simulations, serving pharmaceutical and biotech firms via licensing and collaborative development agreements.
Ownership category
akta.pro rank

Nexilico industry classification

Industry
Product category
Computational Biology / Microbiome Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Microbiome precision medicine
  • Digital twin simulation
  • Computational biology platform
  • AI drug discovery
  • Gut microbiome therapeutics

Where Nexilico is headquartered

Location

Headquarters

HQ city
Danville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nexilico business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing: Licensing of AI-driven microbiome discovery platform and digital twin technology to pharmaceutical and biotech companies for drug discovery and development.
  2. Collaborative Development Agreements: Partnerships with other biotech companies (e.g., Siolta Therapeutics) for co-development of microbiome-based therapeutics with potential milestone and royalty payments.
  3. Government Grants and SBIR Funding: NIH and NSF SBIR/STTR grants providing non-dilutive funding for R&D activities across multiple therapeutic areas.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Nexilico product offering

Product offering

Core offering

Nexilico develops and operates a proprietary Microbiome Digital Twin Platform—an AI-driven, massively parallel computational platform that simulates the dynamic behavior of microbial communities under perturbations, capturing thousands of metabolic features and tracking strain-level responses over time. The platform powers a modality-agnostic discovery engine for designing precision microbiome therapeutics across multiple disease areas (e.g., necrotizing enterocolitis, drug metabolism, xenobiotic toxicity). It has completed over 1.5 million virtual experiments and 40 billion metabolic calculations, providing biotech, pharma, and research collaborators with in silico prediction capabilities that reduce reliance on costly trial-and-error laboratory studies.

Product overview

Nexilico is a biotech company offering a unified precision microbiome engineering platform powered by proprietary AI-driven technology. The core offering consists of the Microbiome Digital Twin Platform, which enables virtualized microbiome experimentation at population scale through in silico simulations (over 1.5 million simulations and 40 billion metabolic calculations). This platform serves as the foundation for specialized applications including the AI-Driven Discovery Platform for precision microbiome therapeutics, the Gut Microbiome Response Prediction Platform for personalized therapeutic response modeling, the Gut Microbiome Drug Metabolism Prediction solution, and the Xenobiotic Toxicity Solution for environmental toxin neutralization. The platform is modality-agnostic, supporting development of diverse therapeutic strategies across multiple disease areas including necrotizing enterocolitis (in partnership with Siolta Therapeutics), metabolic disorders, oncology, and inflammatory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Microbiome Digital Twin Platform A massively parallel simulation platform that models the dynamic behavior of microbial communities under perturbations, capturing interactions across thousands of metabolic features and tracking how microbial strains respond to changes over time. Built on mathematical, biophysical, and systems biology algorithms, it produces the largest virtual microbiome dataset to date. Used by biotech, pharma, and academic collaborators to virtualize microbiome experimentation.
  • AI-Driven Discovery Platform A computational discovery platform based on microbiome digital twin technology that enables disease-agnostic design of precision microbiome therapeutics with enhanced effectiveness as evaluated through microbiome signatures and clinical response. Targeted at biotech and pharmaceutical companies seeking to accelerate microbiome-targeted therapeutic development.
  • Precision Microbiome Engineering Platform A modality-agnostic AI-driven discovery platform that enables microbiome precision medicine and drives the development of diverse therapeutic strategies across a range of diseases, incorporating proprietary microbiome digital twin technology. Designed for biotech and pharma partners seeking integrated precision microbiome engineering capabilities.

Quantifiable outcome

  • 1.5 million virtual experiments completed and 40 billion metabolic calculations simulated
  • +2 more outcomes

Companies that use Nexilico

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Nexilico technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Nexilico partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered supporting, major and core.

  • AWS ActivatesupportingTechnology or Integration · 7 July 2025AWS Activate program providing cloud infrastructure and technical resources that enabled scaling of in silico microbiome simulations to 1.5 million experiments.
  • Google for StartupsmajorTechnology or Integration · 1 April 2025Accepted into Google for Startups Cloud Program at Scale Tier, gaining access to up to $350,000 in Google Cloud credits, expert mentorship, exclusive technical resources, go-to-market guidance, and direct integration with Google Cloud's AI/ML ecosystem.
  • Siolta TherapeuticscoreStrategic or Co-development Partner · 17 September 2024Collaboration agreement to address necrotizing enterocolitis (NEC) using innovative microbial therapeutics. Combines Nexilico's modality-agnostic AI-driven discovery platform with Siolta's end-to-end live biotherapeutic product (LBP) platform. Aims to develop multistrain LBP for preterm infants.
  • NVIDIAmajorTechnology or Integration · 8 March 2024Accepted into NVIDIA Inception Program for AI startups, providing access to advanced computing technologies, expertise, and global network of venture capitalists to accelerate microbiome engineering technology.
  • University of California BerkeleycoreStrategic or Co-development Partner · 13 July 2021Collaboration with UC Berkeley and Microvi Biotech on NIH NCATS grant to develop computational solution for predicting gut microbiome-mediated drug metabolism and its effect on drug efficacy and toxicity.
  • Microvi Biotech Inc.coreStrategic or Co-development Partner · 16 February 2021Collaboration on developing precision biological processes combining Microvi's MicroNiche Engineering (MNE) Platform with Nexilico's machine learning and microbiome modeling platforms. Multiple NIH SBIR grants awarded ($1.12M NIEHS, NCATS funding) for microbiome-based technology development.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Nexilico competitors and assessment

Company assessment

Direct peers

  • Second Genome: Second Genome applies microbiome science to drug discovery in inflammation and metabolic disease, combining computational biology with therapeutic development — a similar platform-plus-pipeline model to Nexilico's digital twin approach.
  • Microvi Biotech: Microvi Biotech provides microbiome-based biocatalysis and precision biological processes, and is Nexilico's repeated NIH co-awardee. Both target microbiome engineering for environmental and biomedical applications, sharing grant funding and research collaboration.
  • Insitro: Insitro combines machine learning with high-throughput biology to discover and develop therapeutics. Like Nexilico, Insitro uses AI-driven predictive modeling as a core platform asset to accelerate drug discovery across multiple indications.
  • Siolta Therapeutics: Siolta Therapeutics develops live biotherapeutic products for inflammatory diseases, including NEC — Nexilico's named collaboration partner. Both companies operate in the microbiome therapeutics space with complementary platforms (computational discovery vs. LBP development).
  • Vedanta Biosciences: Vedanta Biosciences is a clinical-stage microbiome therapeutics company developing defined bacterial consortia for immune-mediated diseases. Comparable as a microbiome drug discovery company pursuing live biotherapeutics, though at significantly larger scale.

Emerging players

  • Turbine AI: Turbine builds AI-driven simulation platforms for cell biology and drug discovery, including in silico experiments on cancer cell behavior. Comparable to Nexilico as an AI simulation platform applied to life sciences R&D, though focused on oncology rather than microbiome.
  • CytoReason: CytoReason builds AI models of the human immune system and disease biology used by pharmaceutical companies for drug discovery. Comparable as an AI-driven biological simulation platform serving pharma/biotech clients, though focused on immune biology rather than microbiome.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo Bioworks is a horizontal synthetic biology platform that designs and programs microbial cells for industrial and biomedical applications. A broad incumbent with a similar platform-plus-applications model but vastly larger scale and capital base.
  • Recursion Pharmaceuticals: Recursion uses high-throughput experimental biology combined with AI/ML to discover new therapeutics. Operates a tech-bio platform similar in spirit to Nexilico's digital twin concept, but at much larger scale with publicly disclosed pipeline programs.
  • Seres Therapeutics: Seres Therapeutics is a clinical-stage microbiome therapeutics company with an approved product (Vowst) and multiple pipeline programs. A broad incumbent in microbiome drug development with established pharma partnerships and much larger capital base than Nexilico.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Nexilico social profiles

Digital presence

Nexilico financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nexilico leadership team

Management profile

Number of profiles

Profiles2 records

Nexilico funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nexilico M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nexilico

What does Nexilico do?

Nexilico develops and operates a proprietary Microbiome Digital Twin Platform—an AI-driven, massively parallel computational platform that simulates the dynamic behavior of microbial communities under perturbations, capturing thousands of metabolic features and tracking strain-level responses over time. The platform powers a modality-agnostic discovery engine for designing precision microbiome therapeutics across multiple disease areas (e.g., necrotizing enterocolitis, drug metabolism, xenobiotic toxicity). It has completed over 1.5 million virtual experiments and 40 billion metabolic calculations, providing biotech, pharma, and research collaborators with in silico prediction capabilities that reduce reliance on costly trial-and-error laboratory studies.

Is Nexilico a public or private company?

Nexilico is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nexilico founded?

Nexilico was founded in 2019. It employs 1 to 10 people.

Where is Nexilico based?

Nexilico is headquartered in Danville, United States, in the North America region.

How does Nexilico make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are collaborative Development Agreements and government Grants and SBIR Funding.

Who are Nexilico's main competitors?

Direct peers on record are Second Genome, Microvi Biotech, Insitro, Siolta Therapeutics and Vedanta Biosciences. Emerging players are Turbine AI and CytoReason. Broad incumbents are Ginkgo Bioworks, Recursion Pharmaceuticals and Seres Therapeutics.

Does Nexilico have an API?

No public API is recorded for Nexilico.

What industry is Nexilico in?

Nexilico's product category is Computational Biology / Microbiome Discovery Platform. Its primary akta.pro industry code is HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals